135 related articles for article (PubMed ID: 26729299)
1. Multinational Evaluation of Mycophenolic Acid, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus Utilization.
Gardiner KM; Tett SE; Staatz CE
Ann Transplant; 2016 Jan; 21():1-11. PubMed ID: 26729299
[TBL] [Abstract][Full Text] [Related]
2. A comparison of mycophenolate use in Australia and Northern Europe, and the impact on the pharmaceutical benefits scheme.
Staatz CE; Smith AJ; Tett SE
Pharmacoepidemiol Drug Saf; 2009 May; 18(5):386-92. PubMed ID: 19253908
[TBL] [Abstract][Full Text] [Related]
3. Utilization of Mycophenolic Acid, Azathioprine, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus: Multinational Study.
Sahman M; Mugosa S; Rancic N
Front Public Health; 2021; 9():671316. PubMed ID: 33869136
[No Abstract] [Full Text] [Related]
4. Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991-2005.
Chang SH; Russ GR; Chadban SJ; Campbell S; McDonald SP
Nephrology (Carlton); 2008 Apr; 13(2):171-6. PubMed ID: 18275507
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of everolimus versus mycophenolate mofetil in combination with cyclosporine and prednisolone in de novo renal transplant recipients.
Holmes M; Chilcott J; Walters S; Whitby S; Akehurst R
Transpl Int; 2004 May; 17(4):182-7. PubMed ID: 15107971
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R
Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
[TBL] [Abstract][Full Text] [Related]
8. Secular Trends in the Cost of Immunosuppressants after Solid Organ Transplantation in the United States.
Helmuth ME; Liu Q; Turenne MN; Park JM; Oguntimein M; Dutcher SK; Balkrishnan R; Sharma P; Zee J; Leichtman AB; Smith AR
Clin J Am Soc Nephrol; 2019 Mar; 14(3):421-430. PubMed ID: 30819667
[TBL] [Abstract][Full Text] [Related]
9. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
[TBL] [Abstract][Full Text] [Related]
10. Tacrolimus Utilization and Expenditure in Serbia.
Rancic N; Vavic N; Obrencevic K; Pilipovic F; Dragojevic-Simic V
Front Public Health; 2017; 5():291. PubMed ID: 29164097
[TBL] [Abstract][Full Text] [Related]
11. Combination of everolimus and tacrolimus in kidney transplant patients with intolerance to mycophenolate mofetil/mycophenolic acid.
Balda S; Inza A; Odriozola N; Zárraga S; García-Erauskin G; Lampreabe I
Transplant Proc; 2009; 41(6):2095-8. PubMed ID: 19715841
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
[TBL] [Abstract][Full Text] [Related]
13. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus.
Kovarik JM; Curtis JJ; Hricik DE; Pescovitz MD; Scantlebury V; Vasquez A
Transplant Proc; 2006 Dec; 38(10):3456-8. PubMed ID: 17175302
[TBL] [Abstract][Full Text] [Related]
14. The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.
Lim WH; Russ GR; Wong G; Pilmore H; Kanellis J; Chadban SJ
Kidney Int; 2017 Apr; 91(4):954-963. PubMed ID: 28109543
[TBL] [Abstract][Full Text] [Related]
15. Trends in maintenance immunosuppressive drugs used in taiwanese kidney transplant recipients: an analysis of the national health insurance research database.
Tsai SF; Cheng CY; Shu KH; Wu MJ
Transplant Proc; 2012 Jan; 44(1):190-2. PubMed ID: 22310612
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation.
Haasova M; Snowsill T; Jones-Hughes T; Crathorne L; Cooper C; Varley-Campbell J; Mujica-Mota R; Coelho H; Huxley N; Lowe J; Dudley J; Marks S; Hyde C; Bond M; Anderson R
Health Technol Assess; 2016 Aug; 20(61):1-324. PubMed ID: 27557331
[TBL] [Abstract][Full Text] [Related]
17. Ultra fast liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of cyclosporin A, tacrolimus, sirolimus, and everolimus in whole blood using deuterated internal standards for cyclosporin A and everolimus.
Meinitzer A; Gartner G; Pilz S; Stettin M
Ther Drug Monit; 2010 Feb; 32(1):61-6. PubMed ID: 20010460
[TBL] [Abstract][Full Text] [Related]
18. The cost effectiveness of tacrolimus versus microemulsified cyclosporin: a 10-year model of renal transplantation outcomes.
Orme ME; Jurewicz WA; Kumar N; McKechnie TL
Pharmacoeconomics; 2003; 21(17):1263-76. PubMed ID: 14986738
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients.
Picard N; Prémaud A; Rousseau A; Le Meur Y; Marquet P
Br J Clin Pharmacol; 2006 Oct; 62(4):477-84. PubMed ID: 16995869
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of sirolimus therapy with early cyclosporin withdrawal vs. long-term cyclosporin therapy in Australia.
Gordois A; Nobes M; Toohey M; Russ G
Clin Transplant; 2006; 20(4):526-36. PubMed ID: 16842533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
